Ticarcillin
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a685037 | 
| Pregnancy category | 
 | 
| Routes of administration | Intravenous | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Protein binding | 45% | 
| Elimination half-life | 1.1 hours | 
| Excretion | Renal | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.047.451 | 
| Chemical and physical data | |
| Formula | C15H16N2O6S2 | 
| Molar mass | 384.42 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Ticarcillin is a carboxypenicillin. It can be sold and used in combination with clavulanate as ticarcillin/clavulanic acid. Because it is a penicillin, it also falls within the larger class of β-lactam antibiotics. Its main clinical use is as an injectable antibiotic for the treatment of Gram-negative bacteria, particularly Pseudomonas aeruginosa and Proteus vulgaris. It is also one of the few antibiotics capable of treating Stenotrophomonas maltophilia infections.
It is provided as a white or pale-yellow powder. It is highly soluble in water, but should be dissolved only immediately before use to prevent degradation.
It was patented in 1963.